Therapeutic approach of a pancreatic Ewing Sarcoma/PNET: case report and literature review

ABSTRACT

Peripheral primitive neuroectodermal tumors (pPNETs) are part of the Ewing sarcoma family. A few more than 30 cases of pPNETs originating on the pancreas have been reported in the consulted literature. We report a locally advanced pancreatic pPNET, with the longest follow-up and survival in the consulted literature, considering quality of life outcomes. 22-year-old male patient, with a pancreatic pPNET comprising pancreatic body and tail with gastric invasion. He underwent multi organic resection and adjuvant chemotherapy and radiotherapy. After 8 years of follow-up, he was free of disease and with a good quality of life self-evaluation. The aggressive surgical approach associated with multimodal regimens provided improvement in disease-free survival and a positive impact on quality of life.

RESUMO

Os tumores neuroectodérmicos primitivos periféricos (pPNETs) fazem parte da família dos sarcomas de Ewing. Pouco mais de 30 casos de pPNETs originários do pâncreas foram relatados na literatura consultada. Relatamos um pPNET pancreático localmente avançado, com o acompanhamento mais longo e sobrevida na literatura consultada, considerando os resultados de qualidade de vida. Paciente do sexo masculino, 22 anos, com pPNET pancreático que compreende corpo e cauda pancreáticos com invasão gástrica. Foi submetido à ressecção multiorgânica e quimioterapia adjuvante e radioterapia. Após 8 anos de acompanhamento, ele estava livre de doenças e com uma autoavaliação de boa qualidade de vida. A abordagem cirúrgica agressiva associada aos esquemas multimodais proporcionou melhora na sobrevida livre de doença e impacto positivo na qualidade de vida.

Keywords:

Neuroectodermal tumors - Primitive - Peripheral - Sarcoma - Ewing - Pancreatic neoplasms - Combined modality therapy - Quality of life

Descritores:

Tumores neuroectodérmicos primitivos periféricos - Sarcoma - Ewing - Neoplasias pancreáticas - Terapia de modalidade combinada - Qualidade de vida

INTRODUCTION

Ewing's sarcoma (ES) is a family of neoplasms arising from ectopic neural and neuroectodermal tissues, first described in 1921. The extraosseous Ewing's sarcoma/ primitive neuroectodermal tumor (EWS/PNET) form was documented in 1969.[1] [2] [3] The translocation (11;22) of the EWSR1 gene (22q12) is the main genetic linkage related to this family of sarcomas.[2] [4]

One of the subtypes of this family is the peripheral primitive neuroectodermal tumor (pPNET). This extremely rare disease affects mainly children, adolescents and young adults.[5] EWS/PNET accounts for 1% of all sarcomas in United States.[6] Usually, the onset is insidious and may be asymptomatic or present signs, and symptoms related to compression of adjacent organs and, mainly, pain.[7]

The prognosis of peripheral primitive neuroectodermal tumor (pPNET) is poor and early detection, complete surgical resection, chemotherapy and radiotherapy are considered standard care.[1] Furthermore, the growth of the lesion itself and aggressive therapy necessary on pancreatic tumors may interfere negatively on some aspects of QoL on longterm follow-up, but this outcome has not been considered in the literature yet, which can highlight the patients' protagonism during his therapy.[8] The longest survival reported was 50 months, in a 31-year-old male patient who had a 10cm pPNET in the pancreatic head and, after Whipple resection only, the tumor recurred and evolved with distant metastasis culminating to his death.[9]

A few more than 30 cases of neuroectodermal primitive tumor originating on pancreas have been documented in the consulted literature. We would like to add a report of a locally advanced pancreatic pPNET treated by European Guidelines at the time, with the longest follow- up, of 8 years, considering quality of life outcomes. The patient signed an informed consent form and agreed to the elaboration of this report.

CASE REPORT

A 22-year-old, male, previously healthy patient presented pain, precocious gastric fullness, abdominal mass and 10kg weight loss for 3 months; imaging exams showed a tumor located in the body and tail of the pancreas about 14cm and gastric invasion ([Figure 1]), clinical staging IV. Due to symptomatic presentation and resectability considered by the team, he underwent R0 surgical resection in 2007. Surgery included resection of pancreatic body and tail, spleen, large omentum, gastric antrum and body (Roux-en-Y reconstruction), a small portion of hepatic segment III, gallbladder and dissection of the hepatic hilus with ligature of the splenic vein by the formation of the portal vein. The surgery lasted 5 hours and required a transfusion of 600ml of packed red blood cells.

Figure 1 Upper left: abdomen CT showing a large tumor in pancreatic body and tail, with approximately 14cm in diameter; Upper right: profile photograph of the abdomen showing tumor in epigastrium; Left and right lower: photographs showing pancreatic tail tumor after retrocavity approach (left) and ligation of the splenic vein in the portal vein formation (right).

Post-operatory histopathologic findings were compatible with poorly differentiated malignant neoplasm with extensive small round cell components. Immunocytochemistry showed CD99 positivity, sarcomeric actin, pan-cytokeratin (AE1-AE3) and neuron-specific enolase strongly suggesting the diagnosis of EWS/PNET sarcoma ([Figure 2]). No cytogenetic studies were performed since they were not available at the time. The treatment was completed with chemotherapy regimen VAC + EI (vincristine 2mg, doxorubicin 120mg, cyclophosphamide 200mg, etoposide 160mg and ifosfamide 2900mg) for 52 weeks, associated with 4500cGy radiotherapy during 6 weeks. The patient answered the SF-36 questionnaire at the last follow-up, eight years after surgery when he was free of disease, which satisfactory results are documented in[Table 1].

Figure 2 Histopathology on hematoxylin-eosin stain. Upper left: 4x objective; Upper right: 10x objective; Lower left: 40x objective; Lower right: 100x objective.

Table 1 Results obtained from patient's answers to SF-36 questionnaire.

Domain	Results
Physical Functioning (PF)	95
Role-Physical (RP)	75
Bodily Pain (BP)	100
General Health (GH)	42
Vitality (VT)	50
Social Functioning (SF)	100
Role-Emotional (RE)	100
Mental Health (MH)	72

DISCUSSION

Ewing's sarcoma/primitive neuroectodermal tumor (EWS/PNET) consists of four sub- types of tumors: Ewing's sarcoma of bone (ESB), extraosseous Ewing's sarcoma (EES), a peripheral primitive neuroectodermal tumor (pPNET) and Askin's tumor.[2] [4] Genetic studies using RT-PCR and FISH correlated the translocation (11;22) of the EWSR1 gene (localization 22q12) with the onset of neoplasia, present in about 90-95% of cases already reported.[3]

In the United States, there are an estimated 13,040 new cases of soft tissue sarcoma and 5,150 deaths due to this type of neoplasia in 2018, of which 1% are EWS/PNET.[6] About 30% of ES are extraosseous with common locations on the soft tissues of extremities, pelvis, retroperitoneum and chest wall.[4] Primary presentations on solid organs such as the kidney, ovary, vagina, testis, uterus, bladder, rectum, parotid, heart, lung and pancreas have also been described.[2] [4]

The poor prognosis associated with these tumors is associated with its aggressive behavior with a tendency to recurrence and metastasis, already reported to lung, bone, bone marrow, liver and lymph nodes.[3] About 25-30% of patients reported on literature presented advanced local disease and early metastasis. The overall survival rate of patients with pPNETs in 5 years is estimated in 50-75%[1] and the longest survival reported was 50 months,[7] and complete long-term remission is 50%.[1] [6]

The diagnosis of EWS/PNET requires the association of diverse information. The suspicious of this tumor should be led by epidemiological data, especially considering a young age when most of the cases are diagnosed and clinical history and examination, which can be unspecific, compatible with growth of the tumor.[1] [2] [4] Clinical presentations described in literature include vague abdominal pain, jaundice, nausea, vomiting, pancreatitis, anemia, hyperglycemia[1] [2] and paraneoplastic syndromes (exophthalmos and precocious puberty).[1] [2]

Imaging exams such as computerized tomography (CT), magnetic resonance imaging (MRI) and ultrasonography (US), also do not show radiologic characteristic signs. However, most tumors are encapsulated, hypoechoic on US, hypodense on CT, iso-hypointense on T1 and hyperintense on T2 on MRI.[2] Some of the differential diagnoses of EES on imaging exams are rhabdomyosarcoma, malignant fibrous histiocytoma and liposarcoma, and, concerning to pancreatic tumors, are exocrine adenocarcinoma and other retroperitoneal tumors.[1] [4] [10]

The histomorphology of ES/PNET shows a poorly differentiated tumor of small round cells requiring a differential diagnosis with several other tumors including lymphoma, Wilms' tumor, neuroblastoma, pancreatoblastoma, pancreatic endocrine tumor, sarcoma and neuroendocrine carcinoma.[1] Confirmation of this diagnosis is possible with immunohistochemical and cytogenetic tumor analyses, in which CD99 (glycoprotein expressed by peripheral primitive neuroectodermal tumors), FLI-1 (DNA binding transcription factors present in ES) positivity and identification of EWSR1 rearrangement establish diagnosis of ES.([1]) When genetic testing is lacking, diagnosis can be based on immunohistochemistry and CD99 testing. Also, positive expression of vimentin, S100 and NSE can be useful, although not specific, and evaluation of negative markers is important on differential diagnosis.[11]

The therapeutic approach of patients with tumors of the Ewing's sarcoma family requires local control of the disease associated with systemic treatment.[2] [10] Some authors suggest that any type of ES can be treated following the algorithm proposed for bone ES. Surgery is the standard treatment for local disease control and it shows to be even more important in EES compared to osseous location.[10]

Complete resection, including tumor-free margins, predicts gain on survival and control of local disease.[4] The quantitative extent of tumor-free margins has not shown to have an important role in oncological results and resection leaving positive margins is associated with worse disease- free survival. However, surgery can be challenging due to morbimortality associated, depending on the extension of tumors at the diagnostic moment and its location such as presented in this case.[9] [10]

EES are radiation sensible, but risks of developing secondary malignancies and advances in surgical techniques restrict its indication. Radiotherapy is mostly indicated in cases of unresectable tumors and should be chosen as the only local control treatment on these cases, since its combination with intralesional resection did not show effectiveness. Neoadjuvant radiotherapy is recommended for locally advanced disease that suggests the surgical approach may leave residual disease.[6] [10] Thus, according to European guidelines, postoperative radiotherapy is indicated in some cases, especially in EES and when there is residual disease after resection.[12] In the case presented, the radiotherapy was indicated due to the extension of the disease.

The inclusion of multi-agent chemotherapy is associated with about 50-60% of improvement in long-term survival. The drugs that constitute the basic scheme in the protocols of most specialized centers are vincristine, cyclophosphamide, doxorubicin, ifosfamide, etoposide and dactinomycin,[1] [2] [12] in which multi-drug schemes including ifosfamide and etoposide have the best outcomes in most cases according to a recent meta-analysis study.[13] In the United States the drugs are administered as 17 cycles of vincristine, doxorubicin and cyclophosphamide, alternating with ifosfamide and etoposide every 3 weeks, over 48 weeks,[1] [2] while European protocols associate vincristine, doxorubicin and alkylating agents with or without etoposide in the same cycle.[2] [10] [12] Chemotherapy is the therapeutic approach for metastatic disease or unresectable recurrent disease and the use of pazopanib has been described in literature on a few cases of EES. For palliative treatment, in cases of recurrence/refractoriness, the combination of etoposide, ifosfamide and cisplatin offers acceptable toxicity.[10] [14]

Due to EWS/PNET aggressiveness and its subsequent hostile therapeutic, there may be a negative impact on the quality of life of patients treated. Quality of life was documented with the Medical Outcomes Study Questionnaire (SF - 36), which consists of 36 items grouped in 8 domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health. Scores values of the 8 domains are calculated, ranging from 0 being the worst to 100 as the best result, for each domain. In the case presented, only two domains (general health and vitality) tended to average scores resulting in great overall quality of life results. Thus, we suggest the adequate treatment provided beneficiated not only survival but also allowed a full life with social relations, without pain and little physical and emotional limitation, according to the patient's perception. Also, the report of QoL provided by the own patient highlights the patients' protagonism during the therapies implemented.[15]

CONCLUSIONS

In conclusion, there have been described in the consulted literature a few more than 30 cases of primitive neuroectodermal tumors of pancreatic origin. In pancreatic neoplasms, primitive neuroectodermal tumors present great diagnostic challenge, and, although rare, should be part of the differential diagnosis of a pancreatic tumor in young patients. The aggressive surgical approach associated with multimodal regimens provided improvement in disease-free survival and a positive impact on the quality of life many years after treatment. The limitation of our conclusion consists of the own case report studies bias.

Conflicts of interest

The authors declare no conflict of interest relevant to this manuscript.

AUTHOR'S CONTRIBUTION

Rodrigo Nascimento Pinheiro: Collection and assembly of data, Data analysis and interpretation, Final approval of manuscript, Manuscript writing, Provision of study materials or patient.

Fabiane Kellem Oliveira dos Santos Cesário: Collection and assembly of data, Final approval of manuscript, Provision of study materials or patient.

José Pablo Mata Mondragon: Collection and assembly of data, Provision of study materials or patient.

Fábio Daniel Barbosa da-Silva: Collection and assembly of data, Data analysis and interpretation, Manuscript writing.

Renata Pereira Fontoura: Conception and design, Data analysis and interpretation, Manuscript writing.

José Donato de Sousa Netto: Data analysis and interpretation, Manuscript writing.

Carlos Henrique de Aguiar Botelho: Collection and assembly of data, Provision of study materials or patient.

• REFERENCES

• Komforti MK, Sokolovskaya E, D'Agostino CA, Benayed R, Thomas RM. Extra-osseous Ewing sarcoma of the pancreas: case report with radiologic, pathologic, and molecular correlation, and brief review of the literature. Virchows Arch 2018; Sep; 473 (03) 361-369
• Saif MW, Kaley K. Extraosseous Ewing's sarcoma of the pancreas: an uncommon but treatable disease. Cureus 2017; 9 (11) e1882
• Jayant K, Agrawal S, Agarwal R, Khoiwal S. Pancreatic Ewings sarcoma - a dreadful tumor. Am J Cancer Prevent 2013; 1 (03) 24-26
• Golhar A, Ray S, Haugk B, Singhvi SK. Cytogenetically confirmed primary Ewing's sarcoma of the pancreas. BMJ Case Rep 2017; May; 2017: bcr219219 https://doi.org/10.1136/bcr-2017-219219
• Esiashvili N, Goodman M, Marcus Junior RB. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol 2008; Jun; 30 (06) 425-430 https://doi.org/10.1097/MPH.0b013e31816e22f3
• Dias A, Arantes T, Sampaio RC, Juredini R, Cunha JEM, Cecconelo I. Pancreatic primitive neuroectdermal tumor: Case Report. Arq Bras Cir Dig 2013; Jun; 26 (02) 159-161
• Kim JY, Song JS, Park H, Byun JH, Song KB, Kim K. et al Primary mesenchymal tumors of the pancreas: single-center experience over 16 years. Pancreas 2014; Aug; 43 (06) 959-968
• Cloyd JM, Cao HST, Petzel MQ, Denbo JW, Parker NH, Nogueras-González GM. et al Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrencefree survivors of pancreatic and periampullary neoplasms. J Surg Oncol 2017; Feb; 115 (02) 144-150
• Perek S, Perek A, Sarman K, Tuzun H, Buyukunal E. Primitive neuroectodermal tumor of the pancreas: a case report of an extremely rare tumor. Pancreatology 2003; 3 (04) 352-356 https://doi.org/10.1159/000071776
• Galyfos G, Karantzikos GA, Kavouras N, Sianou A, Palogos K, Filis K. Extraosseous Ewing sarcoma: diagnosis, prognosis and optimal management. Indian J Surg 2016; Feb; 78 (01) 49-53 https://doi.org/10.1007/s12262-015-1399-0
• Kent I, Edelstein E, Levin O, Wiener Y. Extraosseous Ewing sarcoma arising at the papilla of vater. J Gastrointestin Liver Dis 2018; Mar; 27 (01) 8 https://doi.org/10.15403/jgld.2014.1121.271.ewi
• Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R. et al Bone sarcomas: ESMO- PaedCan-EURACAN Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; Oct; 29 (Suppl 4): iv79-iv95 https://doi.org/10.1093/annonc/mdy310
• Zhang T, Zhang S, Yang F, Wang L, Zhu S, Qiu B. et al Efficacy comparison of six chemotherapeutic combinations for osteosarcoma and Ewing's sarcoma treatment: a network meta-analysis. J Cell Biochem 2018; Jan; 119 (01) 250-259 https://doi.org/10.1002/jcb.25976
• Mori Y, Kinoshita S, Kanamori T, Kataoka H, Joh T, Lida S. et al The successful treatment of metastatic extraosseous Ewing sarcoma with pazopanib. Intern Med 2018; 57 (18) 2753-2757 https://doi.org/10.2169/internalmedicine.9879-17
• Pinheiro RN, Mucci S, Zanatto RM, Picanço Junior OM, Bottino AAG, Fontoura RP. et al Quality of life as a fundamental outcome after curative intent gastrectomy for adenocarcinoma: lessons learned from patients. J Gastrointest Oncol 2019; Oct; 10 (05) 989-998 https://doi.org/10.21037/jgo.2019.06.05

Publikationsverlauf

Eingereicht: 01. Juni 2019

Angenommen: 21. Juli 2019

Artikel online veröffentlicht:
02. Juli 2020